10-K Filing

ALKERMES PLC. CIK: 1520262 FY 2016

Filing Information

Form Type	10-K
Accession Number	`0001520262-17-000007`
Period End Date	20161231
Filing Date	20170217
Fiscal Year	2016
Fiscal Period	FY
XBRL Instance	alks-20161231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 84 Income Statement 74 Cash Flow Statement 104 Stockholders Equity 30 Comprehensive Income 3

Balance Sheet 84 line items

Line Item	Tag	Value	Unit	Period
Preferred stock shares, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock shares, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock shares, authorized	`PreferredStockSharesAuthorized`	50.00M	shares	Point-in-time
Preferred stock shares, authorized	`PreferredStockSharesAuthorized`	50.00M	shares	Point-in-time
Preferred stock shares, issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$186.38M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$224.06M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$181.11M	USD	Point-in-time
Preferred stock shares, issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$167.56M	USD	Point-in-time
Investments - short-term	`AvailableForSaleSecuritiesDebtSecuritiesCurrent`	$310.86M	USD	Point-in-time
Preferred stock shares, outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock shares, outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Investments - short-term	`AvailableForSaleSecuritiesDebtSecuritiesCurrent`	$353.67M	USD	Point-in-time
Receivables, net	`ReceivablesNetCurrent`	$191.10M	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Receivables, net	`ReceivablesNetCurrent`	$155.49M	USD	Point-in-time
Inventory	`InventoryNet`	$38.41M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	450.00M	shares	Point-in-time
Inventory	`InventoryNet`	$63.00M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	450.00M	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$26.29M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	154.19M	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$39.34M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	152.13M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	152.43M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$790.68M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$754.96M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	150.70M	shares	Point-in-time
PROPERTY, PLANT AND EQUIPMENT, NET	`PropertyPlantAndEquipmentNet`	$264.79M	USD	Point-in-time
Treasury stock shares	`TreasuryStockCommonShares`	1.43M	shares	Point-in-time
Treasury stock shares	`TreasuryStockCommonShares`	1.76M	shares	Point-in-time
PROPERTY, PLANT AND EQUIPMENT, NET	`PropertyPlantAndEquipmentNet`	$254.82M	USD	Point-in-time
INTANGIBLE ASSETS - NET	`IntangibleAssetsNetExcludingGoodwill`	$379.19M	USD	Point-in-time
INTANGIBLE ASSETS - NET	`IntangibleAssetsNetExcludingGoodwill`	$318.23M	USD	Point-in-time
INVESTMENTS - LONG-TERM	`MarketableSecuritiesNoncurrent`	$264.07M	USD	Point-in-time
INVESTMENTS - LONG-TERM	`MarketableSecuritiesNoncurrent`	$121.93M	USD	Point-in-time
GOODWILL	`Goodwill`	$92.87M	USD	Point-in-time
GOODWILL	`Goodwill`	$92.87M	USD	Point-in-time
CONTINGENT CONSIDERATION	`BusinessCombinationContingentConsiderationAssetNoncurrent`	$55.30M	USD	Point-in-time
CONTINGENT CONSIDERATION	`BusinessCombinationContingentConsiderationAssetNoncurrent`	$63.20M	USD	Point-in-time
DEFERRED TAX ASSETS	`DeferredTaxAssetsGrossNoncurrent`	$47.77M	USD	Point-in-time
DEFERRED TAX ASSETS	`DeferredTaxAssetsGrossNoncurrent`	$40.86M	USD	Point-in-time
OTHER ASSETS	`OtherAssetsNoncurrent`	$26.96M	USD	Point-in-time
OTHER ASSETS	`OtherAssetsNoncurrent`	$13.68M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$1.86B	USD	Point-in-time
TOTAL ASSETS	`Assets`	$1.73B	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$207.06M	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$168.74M	USD	Point-in-time
Long-term debt-short-term	`LongTermDebtCurrent`	$3.00M	USD	Point-in-time
Long-term debt-short-term	`LongTermDebtCurrent`	$65.74M	USD	Point-in-time
Deferred revenue-short-term	`DeferredRevenueCurrent`	$1.74M	USD	Point-in-time
Deferred revenue-short-term	`DeferredRevenueCurrent`	$1.94M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$211.99M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$236.21M	USD	Point-in-time
LONG-TERM DEBT	`LongTermDebtNoncurrent`	$280.67M	USD	Point-in-time
LONG-TERM DEBT	`LongTermDebtNoncurrent`	$284.21M	USD	Point-in-time
OTHER LONG-TERM LIABILITIES	`OtherLiabilitiesNoncurrent`	$17.16M	USD	Point-in-time
OTHER LONG-TERM LIABILITIES	`OtherLiabilitiesNoncurrent`	$13.08M	USD	Point-in-time
DEFERRED REVENUE-LONG-TERM	`DeferredRevenueNoncurrent`	$7.97M	USD	Point-in-time
DEFERRED REVENUE-LONG-TERM	`DeferredRevenueNoncurrent`	$7.12M	USD	Point-in-time
Total liabilities	`Liabilities`	$541.47M	USD	Point-in-time
Total liabilities	`Liabilities`	$516.94M	USD	Point-in-time
COMMITMENTS AND CONTINGENCIES (Note 16)	`CommitmentsAndContingencies`	-	USD	Point-in-time
COMMITMENTS AND CONTINGENCIES (Note 16)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred shares, par value, $0.01 per share; 50,000,000 shares authorized; zero issued and outstanding at December 31, 2016 and December 31, 2015, respectively	`PreferredStockValue`	-	USD	Point-in-time
Preferred shares, par value, $0.01 per share; 50,000,000 shares authorized; zero issued and outstanding at December 31, 2016 and December 31, 2015, respectively	`PreferredStockValue`	-	USD	Point-in-time
Ordinary shares, par value, $0.01 per share; 450,000,000 shares authorized; 154,191,281 and 152,128,941 shares issued; 152,430,514 and 150,700,989 shares outstanding at December 31, 2016, and December 31, 2015, respectively	`CommonStockValue`	$1.54M	USD	Point-in-time
Ordinary shares, par value, $0.01 per share; 450,000,000 shares authorized; 154,191,281 and 152,128,941 shares issued; 152,430,514 and 150,700,989 shares outstanding at December 31, 2016, and December 31, 2015, respectively	`CommonStockValue`	$1.52M	USD	Point-in-time
Treasury shares, at cost (1,760,767 and 1,427,952 shares at December 31, 2016 and December 31, 2015, respectively)	`TreasuryStockCommonValue`	$72.64M	USD	Point-in-time
Treasury shares, at cost (1,760,767 and 1,427,952 shares at December 31, 2016 and December 31, 2015, respectively)	`TreasuryStockCommonValue`	$58.66M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$2.23B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$2.11B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-3.27M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-3.79M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-947.94M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-739.50M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$1.21B	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$1.40B	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$1.31B	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$1.07B	USD	Point-in-time
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$1.86B	USD	Point-in-time
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$1.73B	USD	Point-in-time

Income Statement 74 line items

Line Item	Tag	Value	Unit	Period
Manufacturing and royalty revenues	`ManufacturingAndRoyaltyRevenues`	$475.29M	USD	Annual
Manufacturing and royalty revenues	`ManufacturingAndRoyaltyRevenues`	$487.25M	USD	Annual
Manufacturing and royalty revenues	`ManufacturingAndRoyaltyRevenues`	$516.88M	USD	Annual
Product sales, net	`SalesRevenueGoodsNet`	$256.15M	USD	Annual
Product sales, net	`SalesRevenueGoodsNet`	$149.03M	USD	Annual
Product sales, net	`SalesRevenueGoodsNet`	$94.16M	USD	Annual
Research and development revenue	`ContractsRevenue`	$7.75M	USD	Annual
Research and development revenue	`ContractsRevenue`	$2.30M	USD	Annual
Research and development revenue	`ContractsRevenue`	$4.02M	USD	Annual
Total revenues	`SalesRevenueNet`	$745.69M	USD	Annual
Total revenues	`SalesRevenueNet`	$618.79M	USD	Annual
Total revenues	`SalesRevenueNet`	$628.34M	USD	Annual
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)	`CostOfGoodsSold`	$138.99M	USD	Annual
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)	`CostOfGoodsSold`	$175.83M	USD	Annual
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)	`CostOfGoodsSold`	$132.12M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$344.40M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$272.04M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$387.15M	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$311.56M	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$374.13M	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$199.91M	USD	Annual
Amortization of acquired intangible assets	`AmortizationOfIntangibleAssets`	$60.96M	USD	Annual
Amortization of acquired intangible assets	`AmortizationOfIntangibleAssets`	$58.15M	USD	Annual
Amortization of acquired intangible assets	`AmortizationOfIntangibleAssets`	$57.69M	USD	Annual
Total expenses	`CostsAndExpenses`	$852.64M	USD	Annual
Total expenses	`CostsAndExpenses`	$705.93M	USD	Annual
Total expenses	`CostsAndExpenses`	$954.36M	USD	Annual
OPERATING LOSS	`OperatingIncomeLoss`	$-224.30M	USD	Annual
OPERATING LOSS	`OperatingIncomeLoss`	$-208.66M	USD	Annual
OPERATING LOSS	`OperatingIncomeLoss`	$-87.14M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$3.33M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$3.75M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$1.97M	USD	Annual
Interest expense	`InterestExpense`	$14.89M	USD	Annual
Interest expense	`InterestExpense`	$13.25M	USD	Annual
Interest expense	`InterestExpense`	$13.43M	USD	Annual
Change in the fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1`	$-2.30M	USD	Annual
Change in the fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1`	$7.90M	USD	Annual
Gain on the Gainesville Transaction	`DisposalGroupNotDiscontinuedOperationGainLossOnDisposal`	$9.64M	USD	Annual
Gain on sale of property, plant and equipment	`GainLossOnSpecificSaleOfPropertyPlantEquipment`	$41.93M	USD	Annual
Gain on sale of property, plant and equipment	`GainLossOnSpecificSaleOfPropertyPlantEquipment`	$2.86M	USD	Annual
Gain on sale of investment in Civitas Therapeutics, Inc.	`AvailableForSaleSecuritiesGrossRealizedGainLossNet1`	$29.56M	USD	Annual
Gain on sale of investment in Acceleron Pharma Inc.	`AvailableForSaleSecuritiesGrossRealizedGainLossNet`	$15.30M	USD	Annual
Other (expense) income, net	`OtherNonoperatingIncomeExpense`	$-2.22M	USD	Annual
Other (expense) income, net	`OtherNonoperatingIncomeExpense`	$-2.48M	USD	Annual
Other (expense) income, net	`OtherNonoperatingIncomeExpense`	$15.00K	USD	Annual
Total other (expense) income, net	`NonoperatingIncomeExpense`	$73.11M	USD	Annual
Total other (expense) income, net	`NonoperatingIncomeExpense`	$-5.72M	USD	Annual
Total other (expense) income, net	`NonoperatingIncomeExpense`	$296.00K	USD	Annual
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-14.03M	USD	Annual
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-224.00M	USD	Annual
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-214.39M	USD	Annual
(BENEFIT) PROVISION FOR INCOME TAXES	`IncomeTaxExpenseBenefit`	$3.16M	USD	Annual
(BENEFIT) PROVISION FOR INCOME TAXES	`IncomeTaxExpenseBenefit`	$-5.94M	USD	Annual
(BENEFIT) PROVISION FOR INCOME TAXES	`IncomeTaxExpenseBenefit`	$16.03M	USD	Annual
NET LOSS	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-30.06M	USD	Annual
NET LOSS	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-208.44M	USD	Annual
NET LOSS	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-227.16M	USD	Annual
Basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-1.38	USD	Annual
Basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.21	USD	Annual
Basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-1.52	USD	Annual
Basic and Diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	151.48M	shares	Annual
Basic and Diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	149.21M	shares	Annual
Basic and Diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	145.27M	shares	Annual
Net loss	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-227.16M	USD	Annual
Net loss	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-208.44M	USD	Annual
Net loss	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-30.06M	USD	Annual
Holding gains (loss), net of a tax provision (benefit) of $237, $(292) and $7,739, respectively	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-661.00K	USD	Annual
Holding gains (loss), net of a tax provision (benefit) of $237, $(292) and $7,739, respectively	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$522.00K	USD	Annual
Holding gains (loss), net of a tax provision (benefit) of $237, $(292) and $7,739, respectively	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$1.59M	USD	Annual
Less: Reclassification adjustment for gains included in net (loss) income	`OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax`	$15.30M	USD	Annual
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-207.92M	USD	Annual
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-227.82M	USD	Annual
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-43.77M	USD	Annual

Cash Flow Statement 104 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-208.44M	USD	Annual
Net loss	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-227.16M	USD	Annual
Net loss	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-30.06M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$98.09M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$94.26M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$85.60M	USD	Annual
Share-based compensation expense	`ShareBasedCompensation`	$59.58M	USD	Annual
Share-based compensation expense	`ShareBasedCompensation`	$94.40M	USD	Annual
Share-based compensation expense	`ShareBasedCompensation`	$97.34M	USD	Annual
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-37.58M	USD	Annual
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-9.69M	USD	Annual
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-19.19M	USD	Annual
Excess tax benefit from share-based compensation	`ExcessTaxBenefitFromShareBasedCompensationOperatingActivities`	$28.58M	USD	Annual
Excess tax benefit from share-based compensation	`ExcessTaxBenefitFromShareBasedCompensationOperatingActivities`	$4.23M	USD	Annual
Excess tax benefit from share-based compensation	`ExcessTaxBenefitFromShareBasedCompensationOperatingActivities`	$32.37M	USD	Annual
Gain on sale of investment in Civitas Therapeutics, Inc.	`AvailableForSaleSecuritiesGrossRealizedGainLossNet1`	$29.56M	USD	Annual
Gain on the Gainesville Transaction	`DisposalGroupNotDiscontinuedOperationGainLossOnDisposal`	$9.64M	USD	Annual
Change in the fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1`	$7.90M	USD	Annual
Change in the fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1`	$-2.30M	USD	Annual
Loss on debt refinancing	`GainsLossesOnExtinguishmentOfDebt`	$-2.08M	USD	Annual
Gain on sale of property, plant and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	$40.10M	USD	Annual
Gain on sale of property, plant and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	$3.27M	USD	Annual
Gain on sale of investment of Acceleron Pharma Inc.	`AvailableForSaleSecuritiesGrossRealizedGainLossNet`	$15.30M	USD	Annual
Other non-cash charges	`OtherNoncashExpense`	$2.94M	USD	Annual
Other non-cash charges	`OtherNoncashExpense`	$9.19M	USD	Annual
Other non-cash charges	`OtherNoncashIncome`	$1.35M	USD	Annual
Receivables	`IncreaseDecreaseInReceivables`	$16.45M	USD	Annual
Receivables	`IncreaseDecreaseInReceivables`	$17.40M	USD	Annual
Receivables	`IncreaseDecreaseInReceivables`	$35.62M	USD	Annual
Inventory	`IncreaseDecreaseInInventories`	$4.21M	USD	Annual
Inventory	`IncreaseDecreaseInInventories`	$-3.69M	USD	Annual
Inventory	`IncreaseDecreaseInInventories`	$26.38M	USD	Annual
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidExpensesAndOtherAssets`	$-15.93M	USD	Annual
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidExpensesAndOtherAssets`	$15.01M	USD	Annual
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidExpensesAndOtherAssets`	$27.03M	USD	Annual
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$56.90M	USD	Annual
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$45.87M	USD	Annual
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$76.16M	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$-629.00K	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$-649.00K	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$-996.00K	USD	Annual
Other long-term liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$3.29M	USD	Annual
Other long-term liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$3.59M	USD	Annual
Other long-term liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$4.59M	USD	Annual
Cash flows (used in) provided by operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$11.14M	USD	Annual
Cash flows (used in) provided by operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-63.80M	USD	Annual
Cash flows (used in) provided by operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-40.36M	USD	Annual
Additions of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$43.66M	USD	Annual
Additions of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$33.65M	USD	Annual
Additions of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$52.88M	USD	Annual
Proceeds from the sale of equipment	`ProceedsFromSaleOfPropertyPlantAndEquipment`	$194.00K	USD	Annual
Proceeds from the sale of equipment	`ProceedsFromSaleOfPropertyPlantAndEquipment`	$44.37M	USD	Annual
Proceeds from the sale of equipment	`ProceedsFromSaleOfPropertyPlantAndEquipment`	$535.00K	USD	Annual
Investment in Reset Therapeutics, Inc.	`PaymentsToAcquireEquityMethodInvestments`	$15.00M	USD	Annual
Purchases of investments	`PaymentsToAcquireMarketableSecurities`	$508.68M	USD	Annual
Purchases of investments	`PaymentsToAcquireMarketableSecurities`	$375.10M	USD	Annual
Purchases of investments	`PaymentsToAcquireMarketableSecurities`	$642.46M	USD	Annual
Sales and maturities of investments	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$341.15M	USD	Annual
Sales and maturities of investments	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$467.57M	USD	Annual
Sales and maturities of investments	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$560.80M	USD	Annual
Net proceeds from the Gainesville Transaction	`ProceedsFromDivestitureOfBusinessesNetOfCashDivested`	$49.97M	USD	Annual
Investment in Civitas Therapeutics, Inc.	`ProceedsFromSaleOfEquityMethodInvestments`	$27.19M	USD	Annual
Cash flows provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$127.24M	USD	Annual
Cash flows provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-263.40M	USD	Annual
Cash flows provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-43.49M	USD	Annual
Proceeds from the issuance of ordinary shares, net	`ProceedsFromIssuanceOfCommonStock`	$248.41M	USD	Annual
Proceeds from the issuance of ordinary shares under share-based compensation arrangements	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions`	$47.58M	USD	Annual
Proceeds from the issuance of ordinary shares under share-based compensation arrangements	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions`	$44.97M	USD	Annual
Proceeds from the issuance of ordinary shares under share-based compensation arrangements	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions`	$20.31M	USD	Annual
Excess tax benefit from share-based compensation	`ExcessTaxBenefitFromShareBasedCompensationFinancingActivities`	$32.37M	USD	Annual
Excess tax benefit from share-based compensation	`ExcessTaxBenefitFromShareBasedCompensationFinancingActivities`	$4.23M	USD	Annual
Excess tax benefit from share-based compensation	`ExcessTaxBenefitFromShareBasedCompensationFinancingActivities`	$28.58M	USD	Annual
Employee taxes paid related to net share settlement of equity awards	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$13.47M	USD	Annual
Employee taxes paid related to net share settlement of equity awards	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$12.84M	USD	Annual
Employee taxes paid related to net share settlement of equity awards	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$25.90M	USD	Annual
Payment made for debt refinancing	`PaymentsOfDebtExtinguishmentCosts`	$3.43M	USD	Annual
Principal payments of long-term debt	`RepaymentsOfLongTermDebt`	$65.81M	USD	Annual
Principal payments of long-term debt	`RepaymentsOfLongTermDebt`	$6.75M	USD	Annual
Principal payments of long-term debt	`RepaymentsOfLongTermDebt`	$6.75M	USD	Annual
Cash flows (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$-58.17M	USD	Annual
Cash flows (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$40.89M	USD	Annual
Cash flows (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$308.76M	USD	Annual
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$56.50M	USD	Annual
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$5.27M	USD	Annual
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-42.95M	USD	Annual
CASH AND CASH EQUIVALENTS - Beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$181.11M	USD	Point-in-time
CASH AND CASH EQUIVALENTS - Beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$167.56M	USD	Point-in-time
CASH AND CASH EQUIVALENTS - Beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$186.38M	USD	Point-in-time
CASH AND CASH EQUIVALENTS - Beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$224.06M	USD	Point-in-time
CASH AND CASH EQUIVALENTS - End of period	`CashAndCashEquivalentsAtCarryingValue`	$224.06M	USD	Point-in-time
CASH AND CASH EQUIVALENTS - End of period	`CashAndCashEquivalentsAtCarryingValue`	$186.38M	USD	Point-in-time
CASH AND CASH EQUIVALENTS - End of period	`CashAndCashEquivalentsAtCarryingValue`	$167.56M	USD	Point-in-time
CASH AND CASH EQUIVALENTS - End of period	`CashAndCashEquivalentsAtCarryingValue`	$181.11M	USD	Point-in-time
Cash paid for interest	`InterestPaid`	$12.49M	USD	Annual
Cash paid for interest	`InterestPaid`	$12.32M	USD	Annual
Cash paid for interest	`InterestPaid`	$12.46M	USD	Annual
Cash paid for taxes	`IncomeTaxesPaid`	$705.00K	USD	Annual
Cash paid for taxes	`IncomeTaxesPaid`	$5.53M	USD	Annual
Cash paid for taxes	`IncomeTaxesPaid`	$2.80M	USD	Annual
Purchased capital expenditures included in accounts payable and accrued expenses	`NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1`	$3.48M	USD	Annual
Purchased capital expenditures included in accounts payable and accrued expenses	`NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1`	$6.05M	USD	Annual
Purchased capital expenditures included in accounts payable and accrued expenses	`NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1`	$5.77M	USD	Annual
Fair value of warrants received as part of the Gainesville Transaction	`DisposalGroupIncludingDiscontinuedOperationFairValueOfWarrants`	$2.12M	USD	Annual
Fair value of contingent consideration received as part of the Gainesville Transaction	`FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetAcquired`	$57.60M	USD	Annual

Stockholders Equity 30 line items

Line Item	Tag	Value	Unit	Period
Tax provision (benefit)	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax`	$7.74M	USD	Annual
Tax provision (benefit)	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax`	$237.00K	USD	Annual
Tax provision (benefit)	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax`	$-292.00K	USD	Annual
BALANCE	`StockholdersEquity`	$1.21B	USD	Point-in-time
BALANCE	`StockholdersEquity`	$1.40B	USD	Point-in-time
BALANCE	`StockholdersEquity`	$1.31B	USD	Point-in-time
BALANCE	`StockholdersEquity`	$1.07B	USD	Point-in-time
Issuance of ordinary shares, net	`StockIssuedDuringPeriodValueNewIssues`	$248.41M	USD	Annual
Issuance of ordinary shares under employee stock plans	`StockIssuedDuringPeriodValueShareBasedCompensation`	$20.31M	USD	Annual
Issuance of ordinary shares under employee stock plans	`StockIssuedDuringPeriodValueShareBasedCompensation`	$44.97M	USD	Annual
Issuance of ordinary shares under employee stock plans	`StockIssuedDuringPeriodValueShareBasedCompensation`	$47.58M	USD	Annual
Receipt of Alkermes' shares for the purchase of stock options or to satisfy minimum tax withholding obligations related to share based awards	`ReceiptOfCompanyStockForPurchaseOfStockOptionsOrToSatisfyMinimumTaxWithholdingObligationsRelatedToStockBasedAwardsValue`	$-13.47M	USD	Annual
Receipt of Alkermes' shares for the purchase of stock options or to satisfy minimum tax withholding obligations related to share based awards	`ReceiptOfCompanyStockForPurchaseOfStockOptionsOrToSatisfyMinimumTaxWithholdingObligationsRelatedToStockBasedAwardsValue`	$-12.84M	USD	Annual
Receipt of Alkermes' shares for the purchase of stock options or to satisfy minimum tax withholding obligations related to share based awards	`ReceiptOfCompanyStockForPurchaseOfStockOptionsOrToSatisfyMinimumTaxWithholdingObligationsRelatedToStockBasedAwardsValue`	$-25.90M	USD	Annual
Share-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$97.62M	USD	Annual
Share-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$59.91M	USD	Annual
Share-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$94.46M	USD	Annual
Excess tax benefit from share-based compensation	`AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation`	$28.58M	USD	Annual
Excess tax benefit from share-based compensation	`AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation`	$1.83M	USD	Annual
Excess tax benefit from share-based compensation	`AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation`	$32.37M	USD	Annual
Unrealized gains (loss) on marketable securities, net of tax provision (benefit) of $237, ($292), and $7,739 for twelve months ended December 2016, 2015 and 2014, respectively	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$-13.71M	USD	Annual
Unrealized gains (loss) on marketable securities, net of tax provision (benefit) of $237, ($292), and $7,739 for twelve months ended December 2016, 2015 and 2014, respectively	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$-659.00K	USD	Annual
Unrealized gains (loss) on marketable securities, net of tax provision (benefit) of $237, ($292), and $7,739 for twelve months ended December 2016, 2015 and 2014, respectively	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$521.00K	USD	Annual
Net income (loss)	`NetIncomeLoss`	$-208.44M	USD	Annual
Net income (loss)	`NetIncomeLoss`	$-227.16M	USD	Annual
Net income (loss)	`NetIncomeLoss`	$-30.06M	USD	Annual
BALANCE	`StockholdersEquity`	$1.31B	USD	Point-in-time
BALANCE	`StockholdersEquity`	$1.21B	USD	Point-in-time
BALANCE	`StockholdersEquity`	$1.40B	USD	Point-in-time
BALANCE	`StockholdersEquity`	$1.07B	USD	Point-in-time

Comprehensive Income 3 line items

Line Item	Tag	Value	Unit	Period
Tax provision (benefit)	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax`	$7.74M	USD	Annual
Tax provision (benefit)	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax`	$237.00K	USD	Annual
Tax provision (benefit)	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax`	$-292.00K	USD	Annual

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.